Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

Executive Summary

Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.

Advertisement

Related Content

Tecfidera Stands Out From The Pack Of 2013 Drug Launches
Business News, In Brief
New Irritable Bowel Disease And Burn Therapies Among Those Recommended By Europe’s CHMP
FDA Lifts Clinical Hold On Lpath’s Wet-AMD Drug Isonep
Roche Upbeat On Recent Launches, Oncology And Actemra To Drive Growth Through Mid-Term
New U.K. NHS Bodies Authorize Avastin Use In AMD As Lucentis Pricing Pressures Continue
With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers
Ready To Launch But Nowhere To Go: Regeneron's Eylea Gets FDA Delay
Eylea Safety Versus Ease Of Reimbursement Frames Advisory Cmte. Discussion Of Dosing
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS053972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel